Fibrinogen as a cardiovascular risk factor - Marker or causal factor?;Fibrinogen som risikofaktor for hjerte- Og karsykdom markør eller patogenetisk faktor?

Tidsskrift for den Norske Laegeforening

Volumn 119, Issue 19, 1999, Pages 2829-2832

  Halvorsen, Sigrun ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FIBRINOGEN;

ADULT; ARTERIOSCLEROSIS; BLOOD; BLOOD VISCOSITY; CARDIOVASCULAR DISEASE; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; REVIEW; RISK FACTOR;

ADULT; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; BLOOD VISCOSITY; CARDIOVASCULAR DISEASES; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0033587889     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Meyers L. Blood fibrinogen in myocardial infarction. Arch Intern Med 1948; 82: 419-21.
2. McDonald L, Edgill M. Coagulability of the blood in ischaemic heart disease. Lancet 1957; 2: 457-60.
3. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR et al. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
4. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
5. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham study. JAMA 1987; 258: 1183-6.
6. Yarnell JWG, Baker IA, Sweetnam PM, Bainton D, O'Brian JR, Whitehead PJ et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. Circulation 1991; 83: 836-44.
7. Cremer P, Nagel D, Bottcher B, Seidel D. Fibrinogen: ein koronarer Risikofaktor. Diagnose Labor 1992; 42: 28-35.
8. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14: 54-9.
9. Woodward M, Lowe G, Rumley A, Tunstall-Pedoe H. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged med and women. Eur Heart J 1998; 19: 55-62.
10. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Int Med 1993; 118: 956-63.
11. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. JAMA 1998; 279: 1477-82.
12. Doolittle RF. Fibrinogen and fibrin. Ann Rev Biochem 1984; 53: 195-229.
13. Dang C, Bell WR. The normal and morbid biology of fibrinogen. Am J Med 1989; 87: 567-76.
14. Cook NS, Ubben D. Fibrinogen as a major risk factor in cardiovascular disease. Trends Pharmacol Sci 1990; 11: 444-51.
15. Smith EB. Fibrinogen, fibrin and the arterial wall. Eur Heart J 1995; 16: 11-5.
16. Folsom AR. Epidemiology of fibrinogen. Eur Heart J 1995; 16 (suppl A): 21-4.
17. Woodhouse PR, Khaw KT, Plummer M, Foley A, Meade TW. Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease. Lancet 1994; 343: 435-9.
18. Humphries SE. Genetic regulation of fibrinogen. Eur Heart J 1995; 16 (suppl A): 16-20.
19. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van der Loo J. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
20. Becker RC, Cannon CP, Bovill EG, Tracy RP, Thompson B, Knatterud GL et al. Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB trial). Am J Cardiol 1996; 78: 142-7.
21. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation 1997; 96: 4204-10.
22. Fowkes FGR. Fibrinogen and peripheral arterial disease. Eur Heart J 1995; 16 (suppl A): 36-41.
23. Banerjee AK, Pearson J, Gilliland E, GOSS D, Lewis JD, Stirling Y et al. A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemostas 1992; 68: 261-3.
24. Wiseman S, Kenchington G, Dain R, Marshall CE, McCollum CN, Greenhalgh RM et al. Influence of smoking and plasma factors on patency of femoropopliteal vein grafts. BMJ 1989; 299: 643-6.
25. Oliver MF. Fibrinogen and coronary heart disease-what does it mean? Eur Heart J 1998; 19: 8-9.
26. Ross T. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
27. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481-7.
28. Ernst E, Resch KL. Therapeutic interventions to lower plasma fibrinogen concentrations. Eur Heart J 1995; 16 (suppl A): 47-53.
29. Nieuwenhuizen W. Biochemistry and measurement of fibrinogen. Eur Heart J1995; 16 (suppl A): 6-10.